Living‑ versus deceased‑donor renal transplant recipients: A comparison on pulmonary complications

Deceased‑donor transplant recipients had a 4.8‑foldrisk of developing pneumonia (odds ratio, 4.8; 95% confidence interval, 1.2–18.6; P = 0.021).CONCLUSION: Deceased‑donor renal transplant recipients are more vulnerable to pulmonarycomplications than are living‑donor ones and should thus be monitored closely.

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:BACKGROUND: In renal transplant recipients, evaluation of pulmonary complications andinvestigation of reduction interventions are important due to the potentially fatal results of pulmonarycomplications after transplant surgery.

📊

Temel Bulgular & Veri:Therefore, we aimed to assess thepulmonary complications in living‑ versus deceased‑donor renal transplant recipients.METHODS: We retrospectively searched the medical records of patients who underwentrenal transplantation in our tertiary referral center between 2013 and 2018.

💡

Sonuç & Katkı:Deceased‑donor transplant recipients had a 4.8‑foldrisk of developing pneumonia (odds ratio, 4.8; 95% confidence interval, 1.2–18.6; P = 0.021).CONCLUSION: Deceased‑donor renal transplant recipients are more vulnerable to pulmonarycomplications than are living‑donor ones and should thus be monitored closely.

🔬Tür:Araştırma Makalesi

📍Kapsam:2013 Verileri

⚙️Değişkenler:Alan Parametreleri

Abstract

BACKGROUND: In renal transplant recipients, evaluation of pulmonary complications andinvestigation of reduction interventions are important due to the potentially fatal results of pulmonarycomplications after transplant surgery. However, data are lacking about pulmonary complications inrenal transplant recipients with living‑ or deceased‑renal donors. Therefore, we aimed to assess thepulmonary complications in living‑ versus deceased‑donor renal transplant recipients.METHODS: We retrospectively searched the medical records of patients who underwentrenal transplantation in our tertiary referral center between 2013 and 2018. Sociodemographiccharacteristics, pulmonary complications, and major comorbidities were compared according to thedonor type (living or deceased).RESULTS: Fifty‑two of 100 transplantations from living donors and 48 of 100 transplantations fromdeceased donors were formed the patient groups. There were no statistically significant differences in termsof sociodemographic and clinical characteristics between the groups except with regard to pneumoniacomplication. The pneumonia rates were 11/48 (22.9%) and 3/52 (5.8%), P = 0.020, for the deceased‑ andliving‑donor renal transplant recipients, respectively. Deceased‑donor transplant recipients had a 4.8‑foldrisk of developing pneumonia (odds ratio, 4.8; 95% confidence interval, 1.2–18.6; P = 0.021).CONCLUSION: Deceased‑donor renal transplant recipients are more vulnerable to pulmonarycomplications than are living‑donor ones and should thus be monitored closely.

🔖

Bu Makaleye Atıf Yap

KILIÇ, M., ALTINOĞLU, A., ÇEVİK, F. T., TOKAC, M., PARLAK, E. S., DUMLU, E. G., KARALEzLİ, A., HASANOGLU, H. C. (2022). Living‑ versus deceased‑donor renal transplant recipients: A comparison on pulmonary complications. Eurasian Journal of Pulmonology, Cilt: 21 - Sayı: 3, 156–160. https://ajindex.com/articles/509650

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

Kupeli E, Ulubay G, Colak T, Ozdemirel TS, Ozyurek BA, Akcay S, et al. Pulmonary complications in renal recipients after transplantation. Transplant Proc 2011;43:551‑3
Pencheva V, Petrova D, Genoz D, Georgiev O. Pulmonary complications as a cause of death after renal transplantation. Open J Intern Med 2014;4:41‑6
Eyüboğlu FÖ, Küpeli E, Bozbaş SS, Ozen ZE, Akkurt ES, Aydoğan C, et al. Evaluation of pulmonary infections in solid organ transplant patients: 12 years of experience. Transplant Proc 2013;45:3458‑61
Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end‑stage renal disease. Chest 2001;120:1883‑7
Miller WT Jr. Pulmonary infections in patients who have received solid organ transplants. Semin Roentgenol 2000;35:152‑70
Katabathina V, Menias CO, Pickhardt P, Lubner M, Prasad SR. Complications of immunosuppressive therapy in solid organ transplantation. Radiol Clin North Am 2016;54:303‑19
Li CJ, Li L. Tacrolimus in preventing transplant rejection in Chinese patients – optimizing use. Drug Des Devel Ther 2015;9:473‑85
Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 2014;190:1168‑76
Cavusoglu C, Cicek‑Saydam C, Karasu Z, Karaca Y, Ozkahya M, Toz H, et al. Mycobacterium tuberculosis infection and laboratory diagnosis in solid‑organ transplant recipients. Clin Transplant 2002;16:257‑61
World Health Organization. Available from: http://apps.who. int/gho/data. [Last accessed on 2018 Jun 06]
Fischer SA, Lu K; AST Infectious Diseases Community of Practice. Screening of donor and recipient in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:9‑21
Fishman JA; AST Infectious Diseases Community of Practice. Introduction: Infection in solid organ transplant recipients. Am J Transplant 2009;9 Suppl 4:S3‑6
Mejie Y, Piersimoni C, Torre‑Cisneros J, Dilektasli AG, Aguado JM. Behalf of the ESCMİD study group of infection in compromised hosts (ESGICH). Clin Microbiol Infect 2014;20:89‑101
Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, et al. The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement. Eur Respir J 2012;40:990‑1013
Mycobacterium tuberculosis. Am J Transplant 2004;4:37‑41. Doi;
Singh N, Paterson DL. Mycobacterium tuberculosi